Marton König

• Rasmussen, Tilde Harridsleff; Schikora-Rustad, Stine; Lorentzen, Åslaug Rudjord; Tran, Trung; Øverås, Mathias Herstad & Myhr, Kjell-Morten [Vis alle 22 forfattere av denne artikkelen] (2026). Low risk of severe COVID-19 in vaccinated people with multiple sclerosis: a nationwide Norwegian study. BMJ Neurology Open. 8(1). doi: 10.1136/bmjno-2026-001556. Fulltekst i vitenarkiv Vis sammendrag

  Background: We aimed to assess antibody responses and COVID-19 outcomes after vaccination in people with multiple sclerosis (pwMS) receiving disease-modifying therapies. Methods: NevroVAX is a Norwegian multicentre cohort study including 3559 pwMS and 449 healthy controls (HCs) who received at least one dose of BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna) or ChAdOx1 (AstraZeneca/Oxford) between January 2021 and December 2022. Data from records, registries, questionnaires and blood samples collected June 2021–November 2023 were analysed. Primary outcomes were humoral immune responses assessed by seroconversion (anti-spike and anti-receptor-binding domain (RBD) IgG ≥5 binding antibody units/mL). Secondary outcomes included quantitative anti-RBD IgG levels, breakthrough SARS-CoV-2 infection, COVID-19-related hospitalisation and death. Associations with breakthrough infection were evaluated using multivariable logistic regression. Results: Among 3559 pwMS, 1201 received anti-CD20 monoclonal antibodies and 324 sphingosine-1-phosphate receptor (S1PR) modulators. After three vaccine doses, seroconversion was observed in 43.0% of anti-CD20-treated patients and 48.4% of S1PR-treated patients. In multivariable analysis, seroconversion was associated with lower risk of breakthrough infection (OR 0.67, 95% CI 0.58 to 0.78). During follow-up, 58 pwMS (1.6%) were hospitalised for COVID-19; 4 (0.1%) required non-invasive ventilatory support, no patients required invasive ventilation and no deaths occurred. Conclusions: Humoral vaccine responses were impaired in pwMS receiving anti-CD20 or S1PR therapies, but severe COVID-19 was rare. These findings support continued vaccination programmes and tailored protective measures for immunomodulated populations.

• Høgestøl, Einar August; Brustad, Åge Winje; Celius, Elisabeth Gulowsen; Meling, Martine; Berg-Hansen, Pål & Kro, Grete Anette Birkeland [Vis alle 13 forfattere av denne artikkelen] (2026). Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab. BMJ Neurology Open. 8(1). doi: 10.1136/bmjno-2025-001477. Fulltekst i vitenarkiv
• Simonsen, Cecilia Smith; König, Marton; Bjelland, Stein Henry; Andersen, Hilde-Marie; Dugstad, Tobias & Torkildsen, Øivind (2026). Managing Relapsing Multiple Sclerosis Across the Lifespan: A Narrative Review with Expert Opinion from Norway. Neurology and Therapy. ISSN 2193-8253. 15, s. 907–923. doi: 10.1007/s40120-026-00909-z. Fulltekst i vitenarkiv Vis sammendrag

  Relapsing multiple sclerosis (RMS) is most often diagnosed in young adulthood but may also manifest during childhood or later in life. The number of older people living with RMS (pwMS) continues to grow as life expectancy increases and MS incidence rises among older adults. This review summarises the principal challenges in managing pwMS at different stages of life. Paediatric-onset RMS: RMS onset in childhood and adolescence is typically characterised by a higher relapse rate. Early diagnosis, timely intervention, and specialised care are essential. Management also requires close collaboration among healthcare providers, families, and educational institutions to help children balance the disease burden with academic, social, and family life. Young adults with RMS: In young adulthood, MS can disrupt education, employment, relationships, and family planning. Individualised treatment strategies and shared decision-making are essential to align disease management with evolving personal and professional goals. Older pwMS: Age-related issues such as immunosenescence, disability progression, comorbidities, polypharmacy, and menopause become increasingly relevant. Vaccination is particularly important given both immunomodulatory therapies and reduced immune resilience associated with immunosenescence. As pwMS age, treatment strategies may include disease-modifying therapy (DMT) de-escalation, discontinuation, or immune reconstitution therapies to reduce long-term immunosuppression. In conclusion, a holistic, pwMS-centred approach is essential to tailor MS management across the lifespan, adjusting to the medical, functional, and psychosocial needs of pwMS at each stage of life.

• Rød, Brit Ellen; Høgestøl, Einar August; Torkildsen, Øivind; Bjørnevik, Kjetil; Gran, Jon Michael & Øverås, Mathias Herstad [Vis alle 10 forfattere av denne artikkelen] (2025). Comparative effectiveness of rituximab and cladribine in relapsing–remitting multiple sclerosis: A target trial emulation. Multiple Sclerosis. ISSN 1352-4585. 31(8), s. 975–984. doi: 10.1177/13524585251342727. Fulltekst i vitenarkiv Vis sammendrag

  Background: Head-to-head comparisons of high-efficacy therapies for relapsing–remitting multiple sclerosis (RRMS) are lacking. We conducted a target trial emulation to compare the long-term effectiveness of rituximab and cladribine. Methods: We estimated the effect of initiating treatment with rituximab versus cladribine using observational data from the Norwegian MS Registry and Biobank at two university hospitals with different treatment strategies. Cumulative incidence and risk differences (RDs) were estimated using weighted Kaplan-Meier estimators, adjusting for baseline covariates. The primary outcome was magnetic resonance imaging (MRI) disease activity, with secondary outcomes including relapses and safety. Results: The study included 285 patients, 159 receiving rituximab and 126 cladribine, with a median follow-up of 4.5 years (interquartile range (IQR): 4.2–4.7). The 4-year risk of new MRI disease activity was 17% (95% confidence interval (CI): 11–23) for rituximab-treated patients and 57% (95% CI: 44–66) for cladribine-treated patients, yielding an RD of 40 percentage-points (95% CI: 28–50). The 4-year RD for relapse was 12 percentage-points (95% CI: 4–19). The incidence of hospitalizations related to potential adverse events was 6.0 per 100 person-years for rituximab and 4 per 100 person-years for cladribine. Conclusion: These findings suggest that rituximab has superior effectiveness compared to cladribine during a median follow-up of 4.5 years.

• Wolf, Asia-Sophia Fumika Michaela; Ravussin, Anthony; König, Marton; Øverås, Mathias Herstad; Solum, Guri & Kjønstad, Ingrid Fadum [Vis alle 18 forfattere av denne artikkelen] (2023). T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis. JCI Insight. 8(12), s. 1–14. doi: 10.1172/jci.insight.165111. Fulltekst i vitenarkiv Vis sammendrag

  Immune responses in people with multiple sclerosis (pwMS) receiving disease-modifying therapies (DMTs) have been of significant interest throughout the COVID-19 pandemic. Lymphocyte-targeting immunotherapies, including anti-CD20 treatments and sphingosine-1-phosphate receptor (S1PR) modulators, attenuate Ab responses after vaccination. Evaluation of cellular responses after vaccination, therefore, is of particular importance in these populations. In this study, we used flow cytometry to analyze CD4 and CD8 T cell functional responses to SARS-CoV-2 spike peptides in healthy control study participants and pwMS receiving 5 different DMTs. Although pwMS receiving rituximab and fingolimod therapies had low Ab responses after both 2 and 3 vaccine doses, T cell responses in pwMS taking rituximab were preserved after a third vaccination, even when an additional dose of rituximab was administered between vaccine doses 2 and 3. PwMS taking fingolimod had low detectable T cell responses in peripheral blood. CD4 and CD8 T cell responses to SARS-CoV-2 variants of concern Delta and Omicron were lower than to the ancestral Wuhan-Hu-1 variant. Our results indicate the importance of assessing both cellular and humoral responses after vaccination and suggest that, even in the absence of robust Ab responses, vaccination can generate immune responses in pwMS.

• Frič, Radek; König, Marton; Due-Tønnessen, Bernt Johan; Ramm-Pettersen, Jon-Terje & Berg-Johnsen, Jon (2023). Long-term outcome of patients treated for craniopharyngioma: a single center experience. British Journal of Neurosurgery. ISSN 0268-8697. doi: 10.1080/02688697.2023.2179600. Fulltekst i vitenarkiv Vis sammendrag

  Purpose Treatment of craniopharyngiomas (CP) is challenging due to their proximity to critical neural structures, risk of serious complications and impaired quality of life after treatment. Recurrences may occur many years after surgical resection. However, long-term outcome data are still scarce. The purpose of this retrospective study was therefore to assess the long-term results after treatment of patients with CP. Material and method Patients surgically treated for a histologically verified CP at Oslo University Hospital between 1992 and 2015 and with at least a 5-year follow-up were included. Patients’ medical records and radiological studies were reviewed. Results Sixty-one patients (mean age 35.8 ± 22.2 years) were included; 18 patients (30%) were children <18 years of age. The incidence for the study period and the referral population was 1.1 cases/million/year, with trimodal peak incidence at 6, 32 and 59 years of age. The commonest presenting symptoms were visual disturbances (62%), headache (43%) and endocrine dysfunction (34%). The transcranial approach was utilized in 79% of patients. Gross total resection (GTR) was achieved in 59%. The surgical complication rate was 20%. Three patients (5%) received radiotherapy or radiosurgery after primary resection. The mean follow-up was 139 ± 76 months, with no patients lost to follow-up. Postoperatively, 59% of patients had panhypopituitarism and 56% diabetes insipidus. Eighteen patients (30%) developed tumour recurrence after a mean follow-up of 26 ± 25 months. The 10-year overall survival (OS) rate was 75%, whereas the disease-specific survival (DSS) rate was 84%, and recurrence-free survival (RFS) 61%. Subtotal resection (STR) (p = .01) and systemic comorbidity (p = .002) were associated with worse DSS. Conclusion Surgical treatment of CP, even though combined with adjuvant radiotherapy in only selected cases, provides good long-time OS and DSS, and relatively good functional outcome in long-term survivors despite postoperative morbidity, particularly endocrine dysfunction. Systemic comorbidity and STR are individual negative prognostic factors.

• Tran, Trung; Vaage, Eline Benno; Mehta, Adi; Chopra, Adity; Tietze, Lisa & Kolderup, Heidi Anette [Vis alle 40 forfattere av denne artikkelen] (2022). Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants. npj Vaccines. 7(1). doi: 10.1038/s41541-022-00586-7. Fulltekst i vitenarkiv Vis sammendrag

  Diagnostic assays currently used to monitor the efficacy of COVID-19 vaccines measure levels of antibodies to the receptor-binding domain of ancestral SARS-CoV-2 (RBDwt). However, the predictive value for protection against new variants of concern (VOCs) has not been firmly established. Here, we used bead-based arrays and flow cytometry to measure binding of antibodies to spike proteins and receptor-binding domains (RBDs) from VOCs in 12,000 serum samples. Effects of sera on RBD-ACE2 interactions were measured as a proxy for neutralizing antibodies. The samples were obtained from healthy individuals or patients on immunosuppressive therapy who had received two to four doses of COVID-19 vaccines and from COVID-19 convalescents. The results show that anti-RBDwt titers correlate with the levels of binding- and neutralizing antibodies against the Alpha, Beta, Gamma, Delta, Epsilon and Omicron variants. The benefit of multiplexed analysis lies in the ability to measure a wide range of anti-RBD titers using a single dilution of serum for each assay. The reactivity patterns also yield an internal reference for neutralizing activity and binding antibody units per milliliter (BAU/ml). Results obtained with sera from vaccinated healthy individuals and patients confirmed and extended results from previous studies on time-dependent waning of antibody levels and effects of immunosuppressive agents. We conclude that anti-RBDwt titers correlate with levels of neutralizing antibodies against VOCs and propose that our method may be implemented to enhance the precision and throughput of immunomonitoring.

• Riise, Jon; Meyer, Saskia; Blaas, Isaac; Chopra, Adity; Tran, Trung & Delic-Sarac, Marina [Vis alle 22 forfattere av denne artikkelen] (2022). Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. British Journal of Haematology. ISSN 0007-1048. 197(6), s. 697–708. doi: 10.1111/bjh.18149. Fulltekst i vitenarkiv Vis sammendrag

  B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination, but effects on CD8 T-cell responses are unknown. Here, we investigated humoral and CD8 T-cell responses following two vaccinations in patients with lymphoma undergoing anti-CD20-mAb therapy as single agent or in combination with chemotherapy or other anti-neoplastic agents during the last 9 months prior to inclusion, and in healthy age-matched blood donors. Antibody measurements showed that seven of 110 patients had antibodies to the receptor-binding domain of the SARS-CoV-2 Spike protein 3–6 weeks after the second dose of vaccination. Peripheral blood CD8 T-cell responses against prevalent human leucocyte antigen (HLA) class I SARS-CoV-2 epitopes were determined by peptide-HLA multimer analysis. Strong CD8 T-cell responses were observed in samples from 20/29 patients (69%) and 12/16 (75%) controls, with similar median response magnitudes in the groups and some of the strongest responses observed in patients. We conclude that despite the absence of humoral immune responses in fully SARS-CoV-2-vaccinated, anti-CD20-treated patients with lymphoma, their CD8 T-cell responses reach similar frequencies and magnitudes as for controls. Patients with lymphoma on B-cell depleting therapies are thus likely to benefit from current coronavirus disease 2019 (COVID-19) vaccines, and development of vaccines aimed at eliciting T-cell responses to non-Spike epitopes might provide improved protection.

• König, Marton; Torgauten, Hilde Marie; Tran, Trung; Holmøy, Trygve; Vaage, John T. & Lund-Johansen, Fridtjof [Vis alle 7 forfattere av denne artikkelen] (2022). Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients with Multiple Sclerosis and Weak Immune Response after COVID-19 Vaccination. JAMA Neurology. ISSN 2168-6149. 79(3), s. 307–309. doi: 10.1001/jamaneurol.2021.5109. Fulltekst i vitenarkiv
• König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie; Tran, Trung; Schikora-Rustad, Stine & Vaage, Eline Benno [Vis alle 22 forfattere av denne artikkelen] (2021). Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. Journal of Neurology, Neurosurgery and Psychiatry. ISSN 0022-3050. doi: 10.1136/jnnp-2021-327612. Fulltekst i vitenarkiv Vis sammendrag

  Introduction The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown. Understanding the development of protective immunity is of paramount importance to fight the COVID-19 pandemic. Objective To characterise humoral immunity after mRNA-COVID-19 vaccination of people with multiple sclerosis (pwMS). Methods All pwMS in Norway fully vaccinated against SARS-CoV-2 were invited to a national screening study. Humoral immunity was assessed by measuring anti-SARS-CoV-2 SPIKE RBD IgG response 3–12 weeks after full vaccination, and compared with healthy subjects. Results 528 pwMS and 627 healthy subjects were included. Reduced humoral immunity (anti-SARS-CoV-2 IgG <70 arbitrary units) was present in 82% and 80% of all pwMS treated with fingolimod and rituximab, respectively, while patients treated with other DMT showed similar rates as healthy subjects and untreated pwMS. We found a significant correlation between time since the last rituximab dose and the development of humoral immunity. Revaccination in two seronegative patients induced a weak antibody response. Conclusions Patients treated with fingolimod or rituximab should be informed about the risk of reduced humoral immunity and vaccinations should be timed carefully in rituximab patients. Our results identify the need for studies regarding the durability of vaccine responses, the role of cellular immunity and revaccinations. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

• König, Marton & Koht, Jeanette (2021). Ensidig rødme eller ensidig blekhet? Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 141(12), s. 1–3. doi: 10.4045/tidsskr.21.0319. Fulltekst i vitenarkiv
• Corniola, Marco Vincenzo; König, Marton & Meling, Torstein Ragnar (2021). STA-MCA Bypass in Carotid Stenosis after Radiosurgery for Cavernous Sinus Meningioma. Cancers. 13. doi: 10.3390/cancers13102420. Fulltekst i vitenarkiv
• König, Marton; Osnes, Terje; Bruland, Øyvind; Hall, Kirsten Sundby; Bratland, Åse & Meling, Torstein Ragnar (2020). The role of adjuvant treatment in craniofacial malignancy: A critical review. Frontiers in Oncology. 10. doi: 10.3389/fonc.2020.01402. Fulltekst i vitenarkiv Vis sammendrag

  Background: Tumors originating from the craniofacial region usually present in a locally advanced stage with frequent involvement of adjacent sites and have a strong tendency for local recurrence in the absence of adjuvant therapy, even when the original surgical resection was presumed to be radical. In the past decades, several advances in the radiological diagnosis and treatment of craniofacial malignancies have been introduced. There are, however, no randomized trials that define the optimal multimodal treatment of these tumors because of their rarity as well as heterogeneity in both histology and site of origin. The aim of this study was to conduct a critical review of the role of adjuvant therapy in the treatment of craniofacial malignancy. Method: We conducted a critical review of the past and contemporary literature available, focusing on adjuvant oncological treatments of the most common craniofacial malignancies. Results: Preoperative radiotherapy can have a documented role in the treatment of olfactory neuroblastoma and soft tissue sarcoma, while preoperative chemotherapy can be advocated in the treatment of sinonasal undifferentiated carcinoma, neuroendocrine carcinoma, olfactory neuroblastoma, and craniofacial sarcoma (both soft-tissue and high-grade osteosarcoma). Postoperative radiotherapy has a well-established role in the treatment of most craniofacial malignancies. The role of postoperative chemotherapy is unclear in most histologies, but is commonly used during the treatment of well-selected cases of paranasal sinus carcinoma, olfactory neuroblastoma, mucosal melanoma, soft tissue sarcoma and high-grade craniofacial osteosarcoma. Discussion: Alongside developments in surgery, there have also been improvements in diagnostics, radiotherapy, and chemotherapy. Implementation of novel radiation techniques allows delivery of higher radiation doses while minimizing irradiation-related morbidity. Better understanding of tumor biology allows the construction of more complex treatment strategies, incorporating adjuvant chemotherapy either pre- or postoperatively. In the era of personalized targeted therapy, rapid strides are being made to identify specific tumor-targets for use of novel biologic agents, with the potential to change current management paradigms.

• König, Marton; Osnes, Terje; Bratland, Åse; Jebsen, Peter Wilhelm & Meling, Torstein Ragnar (2019). Treatment of sinonasal adenocarcinoma: A population-based prospective cohort study. Journal of Neurological Surgery. Part B: Skull Base: an interdisciplinary approach. ISSN 2193-6331. 61(8), s. 627–637. doi: 10.1055/s-0039-1694050. Fulltekst i vitenarkiv Vis sammendrag

  Objectives Sinonasal adenocarcinoma (AC) is a potentially curable disease despite being an aggressive malignancy. Long-term survival can be achieved with early diagnosis and adequate multidisciplinary treatment. Our goal was to evaluate outcomes for patients with AC treated at our institution. Design In a population-based consecutive prospective cohort, we conducted an analysis of all patients treated for surface epithelial AC between 1995 and 2018. Results Twenty patients were included, and follow-up was 100%. The mean follow-up time was 89 months for the entire cohort (112 months for patients with no evidence of disease). Intestinal-type AC was found in 65%, whereas nonintestinal-type AC was found in 35% of all cases; 75% had stage T3/4 disease. Tumor grade was intermediate/high in 65%. Eighteen patients underwent treatment with curative intent (craniofacial resection [CFR] in 61%, transfacial approach in 39%, adjuvant radiotherapy in 89%), achieving negative margins in 56% of cases. Overall survival (OS) rates were 90, 68, and 54% after 2, 5, and 10 years of follow-up, respectively, and the corresponding disease-specific survival (DSS) rates were 90, 73, and 58%. Age over 60 years, tumor with a maxillary origin, and microscopic bone invasion were negative prognostic factors. Radical CFR was correlated with better OS and DSS. Conclusion The high probability of achieving radicality with CFR, the low complication rate, the acceptable toxicity of modern irradiation modalities, and the promising survival rates indicate that this strategy might be considered a safe and an effective option for treating patients with very advanced sinonasal AC.

• König, Marton; Osnes, Terje; Bratland, Åse & Meling, Torstein Ragnar (2019). Squamous Cell Carcinoma of the Paranasal Sinuses: A Single Center Experience. Journal of Neurological Surgery. Part B: Skull Base: an interdisciplinary approach. ISSN 2193-6331. 81(6), s. 664–672. doi: 10.1055/s-0039-1694967. Fulltekst i vitenarkiv Vis sammendrag

  Objective Squamous cell carcinoma (SCC) of the paranasal sinuses is usually diagnosed at an advanced stage, making curative therapy difficult. The goal of this study was to evaluate the management and outcomes of patients with SCC treated at our institution. Methods In a population-based consecutive prospective cohort, we conducted an analysis of all patients treated for SCC between 1988 and 2017. Results A total of 72 patients were included, follow-up was 100%. Mean follow-up was 57 months for the entire cohort, and 108 months for patients with no evidence of disease. Eighty-two percent of all patients had high-stage (T4) disease. Fifty-seven patients underwent treatment with curative intent; consisting of surgery with or without oncologic treatment in 34, and of oncologic treatment only in 23 cases. Fifteen patients received palliative treatment. The rates of overall survival for the entire cohort were 55% at 2, 41% at 5, and 32% at 10 years, and corresponding disease-specific survival (DSS) rates were 55, 45, and 34%, respectively. DSS rates after surgical treatment with curative intent were 81% at 2, 65% at 5, and 54% at 10 years. Retromaxillary involvement and nonradical surgery were negative prognostic factors. Best survival was achieved with the combination of radical surgery and adjuvant oncologic treatment. Conclusion Surgical resection with a curative intent yielded 65% at 5-year DSS even in this cohort of patients with high-stage SCC and is still considered as the treatment of choice, preferably in combination with adjuvant radiation therapy and chemotherapy.

• König, Marton; Osnes, Terje; Jebsen, Peter Wilhelm & Meling, Torstein Ragnar (2018). Craniofacial resection of malignant tumors of the anterior skull base: a case series and a systematic review. Acta Neurochirurgica. ISSN 0001-6268. 160(12), s. 2339–2348. doi: 10.1007/s00701-018-3716-4. Fulltekst i vitenarkiv Vis sammendrag

  Background: Craniofacial resection (CFR) is still considered as the gold standard for managing sinonasal malignancies of the anterior skull base (ASB), while endoscopic approaches are gaining credibility. The goal of this study was to evaluate outcomes of patients who underwent CFR at our institution and to compare our results to international literature. Method: Retrospective analysis of all patients undergoing CFR between 1995 and 2017, and systematic literature review according to the PRISMA statement. Results: 41 patients with sinonasal malignancy (81% with stage T4) of the ASB were included. There was no operative mortality. Complications were observed in 9 cases. We obtained 100% follow-up with mean observation 100 months. Disease-specific survival rates were 90%, 74% and 62% and recurrence-free survival was 85% at two, 72% at five and ten years follow-up, respectively. CFR as primary treatment, en bloc resection, and resection with negative margins correlated to better survival. Recursive partition analysis identified the latter as the most important prognostic factor, regardless surgical technique. The relative risk of non-radicality was significantly higher after piecemeal resection compared to en bloc resection. Compared to 15 original articles, totaling 2603 patients, eligible for review, the present study has the longest follow-up time, the second highest 5-year OS and the third highest 5-year DSS, despite having a higher proportion of patients with high-stage disease. Conclusion: CFR in true en bloc fashion can still be considered as the treatment of choice in cases of advanced-stage sinonasal malignancies invading the ASB.

• König, Marton; Osnes, Terje; Jebsen, Peter Wilhelm; Evensen, Jan Folkvard & Meling, Torstein Ragnar (2017). Olfactory neuroblastoma: a single-center experience. Neurosurgical review. ISSN 0344-5607. 41, s. 323–331. doi: 10.1007/s10143-017-0859-3. Fulltekst i vitenarkiv
• König, Marton Skog Steinberger; Osnes, Terje; Lobmaier, Ingvild Victoria Koren; Bjerkehagen, Bodil; Bruland, Øyvind & Hall, Kirsten Sundby [Vis alle 7 forfattere av denne artikkelen] (2016). Multimodal treatment of craniofacial osteosarcoma with high-grade histology. A single-center experience over 35 years. Neurosurgical review. ISSN 0344-5607. s. 1–12. doi: 10.1007/s10143-016-0802-z. Fulltekst i vitenarkiv Vis sammendrag

  High-grade craniofacial osteosarcoma (CFOS) is an aggressive malignancy with a poor prognosis. Our goals were to evaluate treatment outcomes in those treated at a single referral institution over 35 years and to compare our results to the available literature. A retrospective analysis of all 42 patients treated between 1980 and 2015 at Oslo University Hospital, Norway, identified in a prospectively collected database, was conducted. Mean follow-up was 79.6 months. Overall survival at 2 and 5 years was 70.5 and 44.7%, respectively. The corresponding disease-specific survival rates were 73.0 and 49.8%. Treatment was surgery only in eight cases. Additional therapy was administered in 34 patients: chemotherapy in nine, radiotherapy in seven, and a combination of these in 18 cases. Stratified analysis by resection margins demonstrated significantly better survival at 2 and 5 years after radical surgical treatment. Neoadjuvant chemotherapy and subsequent adequate surgery resulted in better survival than surgery alone. Half of the patients either had a primary or familial cancer predisposition. This is the largest single-center study conducted on high-grade CFOS to date. Our experience indicates that neoadjuvant chemotherapy with complete surgical resection significantly improved survival, compared to surgery alone.

• König, Marton Steinberger; Osnes, Terje & Meling, Torstein (2014). Treatment of esthesioneuroblastomas. Neuro-chirurgie. ISSN 0028-3770. 60(4), s. 151–157. doi: 10.1016/j.neuchi.2014.03.007. Fulltekst i vitenarkiv
• König, Marton Steinberger; Bakke, Jacob; Scheie, David; Sorteberg, Wilhelm & Meling, Torstein (2011). Reactive Expansive Intracerebral Process as a Complication of Endovascular Coil Treatment of an Unruptured Intracranial Aneurysm: Case Report. Neurosurgery. ISSN 0148-396X. 68(5), s. E1468–E1473. doi: 10.1227/NEU.0b013e318210c7c0. Fulltekst i vitenarkiv
• König, Marton; Due-Tønnessen, Bernt Johan; Osnes, Terje; Haugstvedt, Jan-Ragnar & Meling, Torstein (2010). Median facial cleft with a frontoethmoidal encephalocele treated with craniofacial bipartition and free radial forearm flap: a case report. Skull base surgery. ISSN 1052-1453. 20(2), s. 119–123. doi: 10.1055/s-0029-1238216. Fulltekst i vitenarkiv
• König, Marton Skog Steinberger; Due-Tønnessen, Bernt Johan; Osnes, Terje; Haugstvedt, Jan-Ragnar & Meling, Torstein (2010). Median facial cleft with a frontoethmoidal encephalocele treated with craniofacial bipartition and free radial forearm flap. Journal of Neurological Surgery. Part B: Skull Base: an interdisciplinary approach. ISSN 2193-6331. 2(20), s. 119–123. doi: 10.1055/s-0029-1238216. Fulltekst i vitenarkiv
• König, Marton; Mork, Jon; Hall, Kirsten Sundby; Osnes, Terje & Meling, Torstein (2010). Multimodal Treatment of Osteogenic Sarcoma of the Jaw. Skull base surgery. ISSN 1052-1453. 20(3), s. 207–212. doi: 10.1055/s-0029-1246221. Fulltekst i vitenarkiv

Se alle arbeider i NVA

• König, Marton; Holmøy, Trygve; Nygaard, Gro Owren; Riise, Jon; Midtvedt, Karsten & Goll, Guro Løvik [Vis alle 11 forfattere av denne artikkelen] (2026). Vaccination of immunosuppressed patients. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. doi: 10.4045/tidsskr.25.0555. Fulltekst i vitenarkiv
• König, Marton (2025). Anti-CD20 therapies under the stethoscope: A signal from the heart. Multiple Sclerosis. ISSN 1352-4585. doi: 10.1177/13524585251407513. Fulltekst i vitenarkiv
• Tran, Trung; Vaage, Eline Benno; Mehta, Adi; Chopra, Adity; Tietze, Lisa & Kolderup, Heidi Anette [Vis alle 40 forfattere av denne artikkelen] (2023). Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants (npj Vaccines, (2022), 7, 1, (174), 10.1038/s41541-022-00586-7). npj Vaccines. 8(1). doi: 10.1038/s41541-023-00600-6. Fulltekst i vitenarkiv
• Hermansen, My Vuong; Kleggetveit, Inge Petter; Ulvin, Line Bédos; Chawla, Maninder Singh & König, Marton (2023). En mann i 20-årene med svakhet og nummenhet i beina. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 143(1). doi: 10.4045/tidsskr.22.0642. Fulltekst i vitenarkiv
• Rasmussen, Tilde; König, Marton; Lorentzen, Åslaug Rudjord; Schikora-Rustad, Stine; Berge, Tone & Holmøy, Trygve [Vis alle 17 forfattere av denne artikkelen] (2022). Safety of a third SARS CoV 2 mRNA vaccine dose in people with multiple sclerosis. Fulltekst i vitenarkiv
• König, Marton; Wolf, Asia-Sophia Fumika Michaela; Ravussin, Anthony; Chopra, Adity; Tran, Trung & Torgauten, Hilde Marie [Vis alle 28 forfattere av denne artikkelen] (2022). Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis. Fulltekst i vitenarkiv
• Nygaard, Gro Owren; Schikora-Rustad, Stine; Lie, Ingeborg Haugesag; Aase, Audun; Leiknes, Ingvild Jullum & König, Marton [Vis alle 15 forfattere av denne artikkelen] (2021). Humoral immune response to the influenza vaccine in multiple sclerosis patients treated with cladribine or rituximab. Fulltekst i vitenarkiv
• König, Marton; Lorentzen, Åslaug Rudjord; Torgauten, Hilde Marie; Tran, The Trung; Schikora-Rustad, Stine & Vaage, Eline Benno [Vis alle 22 forfattere av denne artikkelen] (2021). Humoral Immunity to SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis using High-Efficacy Disease Modifying Therapies. Fulltekst i vitenarkiv
• Ghali, Michael G.Z.; Ghali, George Zaki; Lima, Adriana; McDermott, Michael; Glover, Emma & Voglis, Stefanos [Vis alle 12 forfattere av denne artikkelen] (2021). Retraction: Mechanisms underlying the generation of autonomorespiratory coupling amongst the respiratory central pattern generator, sympathetic oscillators, and cardiovagal premotoneurons (Journal of Integrative Neuroscience (2020) 19 (521-560) DOI: 10.31083/j.jin.2020.03.0196). Journal of Integrative Neuroscience (JIN). ISSN 0219-6352. 20(2), s. 527–527. doi: 10.31083/j.jin.2020.03.0196R. Fulltekst i vitenarkiv
• König, Marton (2020). Skjulte skatter. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. doi: 10.4045/tidsskr.20.0622. Fulltekst i vitenarkiv
• König, Marton (2020). Hidden treasures. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. doi: 10.4045/tidsskr.20.0622. Fulltekst i vitenarkiv
• König, Marton (2019). Hva ville Ole Brumm sagt? Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 139(16). doi: 10.4045/tidsskr.19.0679. Fulltekst i vitenarkiv
• Meling, Torstein Ragnar & König, Marton (2019). Bifrontal craniotomy. I Raabe, Andreas (Red.), The Craniotomy Atlas. Thieme Medical Publishers. ISSN 9783132057913. s. 112–118. Fulltekst i vitenarkiv Vis sammendrag

  Given that the great majority of brain surgeries are preceded by a craniotomy, mastering the procedure is essential for junior residents. Choosing the appropriate craniotomy and executing it safely is the difference between a straightforward case with good access to the target and a procedure where access to the target is needlessly traumatic and may even be impossible. Professor Raabe's The Craniotomy Atlas provides precise instructions for performing all common neurosurgical cranial exposures, including: convexity approaches, midline approaches, skull base approaches, transsphenoidal approaches and more. Instructions for each craniotomy include positioning, head fixation, aesthetic considerations, and protecting the dura mater.

• König, Marton (2019). Hodepine hos barn. Fulltekst i vitenarkiv
• König, Marton; Osnes, Terje; Jebsen, Peter Wilhelm; Bratland, Åse & Meling, Torstein Ragnar (2018). Squamous cell carcinoma of the paranasal sinuses: a single center experience. Fulltekst i vitenarkiv
• König, Marton; Osnes, Terje; Jebsen, Peter Wilhelm & Meling, Torstein Ragnar (2018). Craniofacial resection of malignant tumors of the anterior skull base. Fulltekst i vitenarkiv
• Rutherford, Ole-Christian Walter; König, Marton; Risnes, Klaus; Raouf, Nezar; Atar, Dan & Ghanima, Waleed Khalid (2018). O-C.W. Rutherford og medarbeidere svarer. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 138(7), s. 621–621. doi: 10.4045/tidsskr.18.0238. Fulltekst i vitenarkiv
• Rutherford, Ole-Christian Walter; König, Marton; Risnes, Klaus; Raouf, Nezar; Atar, Dan & Ghanima, Waleed Khalid (2018). Antidotbehandling ved bruk av direktevirkende antikoagulasjonsmidler. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 138(3), s. 244–247. doi: 10.4045/tidsskr.17.0190. Fulltekst i vitenarkiv
• König, Marton; Osnes, Terje; Jebsen, Peter Wilhelm; Evensen, Jan Folkvard & Meling, Torstein Ragnar (2018). Olfactory neuroblastoma: a single-center experience. Fulltekst i vitenarkiv
• König, Marton (2017). M. König svarer. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 137(4), s. 260–261. doi: 10.4045/tidsskr.17.0103. Fulltekst i vitenarkiv
• Meling, Torstein Ragnar; König, Marton; Jebsen, Peter Wilhelm; Evensen, Jan Folkvard & Osnes, Terje (2017). Olfactory neuroblastoma: a single-center experience. Fulltekst i vitenarkiv
• König, Marton (2017). M. Konig svarer:. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 137(4), s. 260–261. doi: 10.4045/tidsskr.17.0103. Fulltekst i vitenarkiv
• König, Marton (2016). Akutte nevrologer. [Journal]. Tidsskrift for Den norske legeforening (Tidsskriftet). doi: 10.4045/tidsskr.16.0762. Fulltekst i vitenarkiv
• König, Marton Skog Steinberger; Osnes, Terje; Lobmaier, Ingvild Victoria Koren; Bjerkehagen, Bodil; Bruland, Øyvind & Hall, Kirsten Sundby [Vis alle 7 forfattere av denne artikkelen] (2016). Craniofacial Osteosarcoma: A Single-Institution Experience. Fulltekst i vitenarkiv
• König, Marton Skog Steinberger; Osnes, Terje; Lobmaier, Ingvild Victoria Koren; Bjerkehagen, Bodil; Bruland, Øyvind & Hall, Kirsten Sundby [Vis alle 7 forfattere av denne artikkelen] (2016). Treatment of Craniofacial Osteosarcoma: a Multidisciplinary Approach. Fulltekst i vitenarkiv
• König, Marton; Osnes, Terje & Meling, Torstein R. (2012). Treatment of Esthesioneuroblastomas: a Single Institution Experience. Fulltekst i vitenarkiv
• König, Marton; Mork, Jon; Hall, Kirsten Sundby; Osnes, Terje & Meling, Torstein R. (2009). Treatment of Osteogenic Sarcoma of the Jaw: a Case Report. Fulltekst i vitenarkiv

Se alle arbeider i NVA